Literature DB >> 10933727

Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest.

M P Sherman1, C M de Noronha, D Pearce, W C Greene.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) Vpr participates in nuclear targeting of the viral preintegration complex in nondividing cells and induces G(2) cell cycle arrest in proliferating cells, which creates an intracellular milieu favorable for viral replication. Vpr also activates the transcription of several promoters and enhancers by a poorly understood mechanism. Vpr enhances glucocorticoid receptor (GR) signaling and may mediate the effects of steroids on HIV replication. More specifically, recombinant Vpr can potentiate virion production from U937 cells, downregulate NF-kappaB induction, and enhance programmed cell death, all effects also mediated by glucocorticoids. Vpr has been proposed to act as a GR coactivator, although other studies suggest that these enhancing effects are merely a consequence of G(2) cell cycle arrest. We now demonstrate that Vpr functions as a GR coactivator and that this activity is independent of cell cycle arrest. In addition, we show that the Vpr-induced coactivation requires an intact glucocorticoid response element, that it is dependent on the presence of hormone and the corresponding receptor, and that it is mediated by the two highly conserved leucine-rich domains within Vpr that resemble the GR coactivator signature motif.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933727      PMCID: PMC112350          DOI: 10.1128/jvi.74.17.8159-8165.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation.

Authors:  S A Stewart; B Poon; J Y Song; I S Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Identification of HIV-1 vpr product and function.

Authors:  E A Cohen; E F Terwilliger; Y Jalinoos; J Proulx; J G Sodroski; W A Haseltine
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

3.  Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis.

Authors:  C Brostjan; J Anrather; V Csizmadia; D Stroka; M Soares; F H Bach; H Winkler
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

4.  Steroid receptor transcriptional synergy is potentiated by disruption of the DNA-binding domain dimer interface.

Authors:  W Liu; J Wang; G Yu; D Pearce
Journal:  Mol Endocrinol       Date:  1996-11

5.  Characterization of a leucine-zipper-like domain in Vpr protein of human immunodeficiency virus type 1.

Authors:  L Wang; S Mukherjee; O Narayan; L J Zhao
Journal:  Gene       Date:  1996-10-31       Impact factor: 3.688

6.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors.

Authors:  D M Heery; E Kalkhoven; S Hoare; M G Parker
Journal:  Nature       Date:  1997-06-12       Impact factor: 49.962

7.  The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB.

Authors:  I Agostini; J M Navarro; F Rey; M Bouhamdan; B Spire; R Vigne; J Sire
Journal:  J Mol Biol       Date:  1996-09-06       Impact factor: 5.469

8.  Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM).

Authors:  T M Fletcher; B Brichacek; N Sharova; M A Newman; G Stivahtis; P M Sharp; M Emerman; B H Hahn; M Stevenson
Journal:  EMBO J       Date:  1996-11-15       Impact factor: 11.598

9.  GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors.

Authors:  H Hong; K Kohli; M J Garabedian; M R Stallcup
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

10.  GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors.

Authors:  H Hong; K Kohli; A Trivedi; D L Johnson; M R Stallcup
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

View more
  22 in total

Review 1.  HIV-1 Vpr: mechanisms of G2 arrest and apoptosis.

Authors:  Joshua L Andersen; Erwann Le Rouzic; Vicente Planelles
Journal:  Exp Mol Pathol       Date:  2008-04-25       Impact factor: 3.362

2.  Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr.

Authors:  M P Sherman; C M de Noronha; M I Heusch; S Greene; W C Greene
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Equine infectious anemia virus Gag p9 function in early steps of virus infection and provirus production.

Authors:  Sha Jin; Chaoping Chen; Ronald C Montelaro
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 4.  Adipose Tissue in HIV Infection.

Authors:  John R Koethe
Journal:  Compr Physiol       Date:  2017-09-12       Impact factor: 9.090

5.  The respiratory syncytial virus (RSV) nonstructural proteins mediate RSV suppression of glucocorticoid receptor transactivation.

Authors:  Jeanette I Webster Marketon; Jacqueline Corry; Michael N Teng
Journal:  Virology       Date:  2013-11-26       Impact factor: 3.616

Review 6.  Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection.

Authors:  Marni N Silverman; Brad D Pearce; Christine A Biron; Andrew H Miller
Journal:  Viral Immunol       Date:  2005       Impact factor: 2.257

7.  Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators.

Authors:  Tomoshige Kino; Alexander Gragerov; Olga Slobodskaya; Maria Tsopanomichalou; George P Chrousos; George N Pavlakis
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases.

Authors:  Yong Xiao; Gang Chen; Jonathan Richard; Nicole Rougeau; Hongshan Li; Nabil G Seidah; Eric A Cohen
Journal:  Virology       Date:  2007-12-03       Impact factor: 3.616

9.  The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection.

Authors:  Laurieann Casey Klockow; Hamayun J Sharifi; Xiaoyun Wen; Meg Flagg; Andrea K M Furuya; Michael Nekorchuk; Carlos M C de Noronha
Journal:  Virology       Date:  2013-07-09       Impact factor: 3.616

10.  Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy.

Authors:  Shashi Shrivastav; Tomoshige Kino; Tshaka Cunningham; Takamasa Ichijo; Ulrich Schubert; Peter Heinklein; George P Chrousos; Jeffrey B Kopp
Journal:  Mol Endocrinol       Date:  2007-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.